CoChat

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial

Open access
Schneider, Lon S., Frangakis, Constantine, Drye, Lea T., Devanand, D.P., Marano, Christopher M., Mintzer, Jacob, Mulsant, Benoit H., Munro, Cynthia A., Newell, Jeffery A., Pawluczyk, Sonia, Pelton, Gregory, Pollock, Bruce G., Porsteinsson, Anton P., Rabins, Peter V., Rein, Lisa, Rosenberg, Paul B., Shade, David, Weintraub, Daniel, Yesavage, Jerome, Lyketsos, Constantine G., for the CitAD Research Group · 2016 · American Journal of Psychiatry
Cited by 95

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Pharmacological treatments for agitation and aggression in patients with Alzheimer's disease have shown limited efficacy. The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed. METHOD: In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disease and clinically significant agitation, participants were randomly assigned to receive citalopram or placebo for 9 weeks, with the dosage titrated to 30 mg/day over the first 3 weeks. Five planned potential predictors of treatment outcome were assessed, along with six additional predictors. The authors then used a two-stage multivariate method to select the most likely predictors; grouped participants into 10 subgroups by their index scores; and estimated the citalopram treatment effect for each. RESULTS: Five covariates were likely predictors, and treatment effect was heterogeneous across the subgroups. Patients for whom citalopram was more effective were more likely to be outpatients, have the least cognitive impairment, have moderate agitation, and be within the middle age range (76-82 years). Patients for whom placebo was more effective were more likely to be in long-term care, have more severe cognitive impairment, have more severe agitation, and be treated with lorazepam. CONCLUSIONS: Considering several covariates together allowed the identification of responders. Those with moderate agitation and with lower levels of cognitive impairment were more likely to benefit from citalopram, and those with more severe agitation and greater cognitive impairment were at greater risk for adverse responses. Considering the dosages used and the association of citalopram with cardiac QT prolongation, use of this agent to treat agitation may be limited to a subgroup of people with dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.15050648

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 95

Metadata

Authors
Schneider, L. S., Frangakis, C., Drye, L. T., Devanand, D. P., Marano, C. M., Mintzer, J., Mulsant, B. H., Munro, C. A., Newell, J. A., Pawluczyk, S., Pelton, G., Pollock, B. G., Porsteinsson, A. P., Rabins, P. V., Rein, L., Rosenberg, P. B., Shade, D., Weintraub, D., Yesavage, J., Lyketsos, C. G., & for the CitAD Research Group
Venue
American Journal of Psychiatry
Published
2016-05-01
Volume
173
Issue
5
Pages
465-472
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2236030964
Cited by
95
References
11
FWCI
6.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2015.15050648
The paper
Schneider, L. S., Frangakis, C., Drye, L. T., Devanand, D. P., Marano, C. M., Mintzer, J., Mulsant, B. H., Munro, C. A., Newell, J. A., Pawluczyk, S., Pelton, G., Pollock, B. G., Porsteinsson, A. P., Rabins, P. V., Rein, L., Rosenberg, P. B., Shade, D., Weintraub, D., Yesavage, J., . . . for the CitAD Research Group. (2016). Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15050648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.